ADMA Biologics (NASDAQ:ADMA) Stock Price Down 5.5% – Time to Sell?

ADMA Biologics Inc (NASDAQ:ADMA)’s stock price traded down 5.5% during trading on Tuesday . The stock traded as low as $8.66 and last traded at $8.6350. 452,434 shares were traded during trading, a decline of 89% from the average session volume of 4,254,918 shares. The stock had previously closed at $9.14.

Wall Street Analysts Forecast Growth

ADMA has been the topic of a number of research analyst reports. Raymond James Financial initiated coverage on ADMA Biologics in a report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price target on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 2nd. Finally, Mizuho reduced their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $18.67.

ADMA Biologics Stock Performance

The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. The company has a market capitalization of $1.96 billion, a PE ratio of 12.48 and a beta of 0.78. The company has a 50 day moving average of $9.23 and a two-hundred day moving average of $9.99.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The firm had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. During the same period in the prior year, the firm earned $0.14 EPS. The company’s revenue was up 2.0% compared to the same quarter last year. As a group, equities research analysts predict that ADMA Biologics Inc will post 0.78 earnings per share for the current year.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of ADMA Biologics during the second quarter valued at $321,037,000. Sachem Head Capital Management LP increased its stake in ADMA Biologics by 27.0% during the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after purchasing an additional 2,415,000 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in ADMA Biologics by 36.9% in the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock worth $127,551,000 after buying an additional 1,886,105 shares during the last quarter. Capital Research Global Investors raised its holdings in ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after buying an additional 3,383,559 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of ADMA Biologics by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 5,830,941 shares of the biotechnology company’s stock worth $106,374,000 after buying an additional 17,203 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for patients with compromised or inadequate immune systems. The company’s activities include operating plasma collection centers, sourcing human plasma, and producing specialized immunoglobulin therapies.

ADMA’s marketed products include ASCENIV, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency disease; BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, a hepatitis B immune globulin used to provide protection against hepatitis B infection in certain clinical settings.